# CaaMTech

> CaaMTech is an Issaquah, Washington drug discovery company building patentable, psychedelic-inspired medicines. Founded in 2016 by chemist and patent attorney Andrew Chadeayne, it has synthesized and characterized a large library of novel tryptamines, solved crystal structures of compounds like 4-AcO-DMT and norpsilocin, and filed more than 100 patent applications. The company studies the 'entourage effect' in magic mushrooms to engineer compounds that keep the benefits while reducing side effects, and in 2021 raised a $22M Series A to push lead candidates toward human trials.

- **Founded:** 2016
- **Headquarters:** Issaquah, Washington, United States
- **Founders:** Andrew Chadeayne (Founder & CEO)
- **Team size:** ~8 employees
- **Products:** Novel tryptamine compound library, Prophoria and Amphoria, Crystal structure / chemical characterization research, Intellectual property portfolio, Transneural Therapeutics (spin-out)
- **Notable:** Filed more than 100 patent applications, one of the largest IP portfolios in psychedelic drug discovery., Solved and published crystal structures of multiple tryptamines (4-AcO-DMT, MPT, norpsilocin, 5-MeO-DALT)., Raised an oversubscribed $22M Series A led by Noetic Fund in 2021.

## Products & services

- **Novel tryptamine compound library** — A large portfolio of synthesized and chemically characterized novel molecules related to those found in 'magic' mushrooms, designed to optimize desired effects while minimizing unwanted side effects.
- **Prophoria and Amphoria** — A novel tryptamine (Prophoria) designed as a prodrug analogue of aeruginascin that is metabolized into Amphoria, offering a cheaper, easier route to delivering aeruginascin's active metabolite.
- **Crystal structure / chemical characterization research** — Published crystal structures of tryptamines including 4-AcO-DMT (psilacetin), MPT, norpsilocin and 5-MeO-DALT - foundational data for safe, reproducible drug development.
- **Intellectual property portfolio** — More than 100 patent applications covering psychedelic compounds, formulations, and tryptamine-cannabinoid combinations.
- **Transneural Therapeutics (spin-out)** — A 2025 spin-out developing non-hallucinogenic neuroplastogens for depression and PTSD, with a lead candidate in the IND-enabling stage.

## Achievements

- Filed more than 100 patent applications, one of the largest IP portfolios in psychedelic drug discovery.
- Solved and published crystal structures of multiple tryptamines (4-AcO-DMT, MPT, norpsilocin, 5-MeO-DALT).
- Raised an oversubscribed $22M Series A led by Noetic Fund in 2021.
- Synthesized novel tryptamines Prophoria and Amphoria as a cost-effective route to aeruginascin's active metabolite.
- Received patent allowance for tryptamine-cannabinoid combination compounds.
- Spun out Transneural Therapeutics (2025) to develop non-hallucinogenic neuroplastogens.

## Latest updates

- **2025-04** — Spun out Transneural Therapeutics to develop non-hallucinogenic neuroplastogens for depression and PTSD; lead candidate in IND-enabling stage.
- **2021-09** — Closed $22M Series A led by Noetic Fund to advance lead candidates toward human trials.
- **2021-11** — Teamed with the University of Wyoming to study psychedelics as treatments for addiction.

## Links

- Website: https://caam.tech
- LinkedIn: http://www.linkedin.com/company/caamtech
- Twitter/X: https://twitter.com/CaaMTechInc
- Facebook: https://www.facebook.com/CaaMTechInc/

---

Profile page: https://yespress.io/caamtech
Published by YesPress — https://yespress.io
Last updated: 2026-06-15